Safety of amisulpride (Solian®): A review of 1 clinical studies

International Clinical Psychopharmacology

Volumn 14, Issue 4, 1999, Pages 209-218

  Coulouvrat, C ^a   Dondey Nouvel, L ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BLOOD CELL COUNT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 0032812653     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199907000-00002     Document Type: Article

References (33)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Andreasen N (1983a) The Scale for the Assessment of Negative Symptoms (SANS). Iowa: The University of Iowa.
4. Andreasen N (1983b) The Scale for the Assessment of Positive Symptoms (SAPS). Iowa: The University of Iowa.
5. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
6. Barnes TR, Trauer T (1982) Reliability and validity of a tardive dyskinesia videotape rating technique. Br J Psychiatry 140:508-515.
7. Bénichou C (1994) Adverse Drug Reactions. A Practical Guide to Diagnosis and Management. Chichester: John Wiley & Sons.
8. Bobon DP (1981) Le Système AMDP. Brussels: Mardaga.
9. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72.
10. Casey D (1997) Will the new antipsychotics bring hope of reducing the risk of developing extra-pyramidal syndromes and tardive dyskinesia? International Clin Psychopharmacology 12 (Suppl. 1):19-27.
11. Colonna L, Turjanski S, Dondey-Nouvel L (1998) Amisulpride - Long-term safey. Abstracts of the XIth Congress of Neuropsychopharmacology, Vol. 8, suppl. 2, p. 5246.
12. Danion, JM, Rein W, Fleurot O, et al., the Amisulpride Study Group (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 156:610-616.
13. Fleischhacker, WW, Bergman, KJ, Perovich R, et al. (1989) The Hillside akathisia scale, a new rating instrument for neuroleptic induced akathisia. Psychopharmacol Bull 22:222-226.
14. Fleurot O, Rein W (1997) Continuing pharmaconeuroendocrinological long-term trial in patients treated during BENASLP study (lab. 88228). Synthelabo Group. Report No. 95-00756-EN-00. France: Le Plessis-Robinson.
15. Fleurot O, Bech P, Turjanski S (1997) Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiatry 42:1S-194S.
16. Hugh G (1994) Clinical relationship of extra-pyramidal symptoms and tardive dyskinesia. Can J Psychiatry 39 (Suppl. 2):576-580.
17. Krawiecka M, Goldberg D, Vaughan M (1979) A standardised psychiatric assessment scale for rating clinical psychiatric patients. Acta Psychiatr Scand 55:299-308.
18. lingjaerde O, Ahlfors, UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side-effect rating scale. Acta Psychiatr Scand 76 (Suppl. 334):81-101.
19. Loo H, Poirier-Littré, MF, Théron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18-22.
20. Madhusoodanan S, Brenner R (1996) Risperidone-induced ejaculatory and urinary dysfunction. J Clin Psychiatry 57:549-550.
21. Möller, HJ, Boyer P, Fleurot O, et al. (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132:396-401.
22. National Institute of Mental Health (1976) AIMS. Abnormal Involuntary Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology, rev. edn (Guy W, ed.), NIMH: Rockville, MD. pp. 534-537.
23. Overall, JF, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
24. Owens DG (1994) Extra-pyramidal side-effects and tolerability of risperidone: a review. J Clin Psychiatry 55 (Suppl. 5):29-35.
25. Penn, JV, Martini J, Radka D (1996) Weight gain associated with risperidone. J Clin Psychopharmacol 16:259-260.
26. Paillère-Martinot, ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130-133.
27. Perrault G, Depoortere R, Morel E, Sanger D, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82.
28. Puech, AJ, Fleurot O, Rein W, and the Amisulpride Study Group (1998) Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatrica Scand 98:65-72.
29. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
30. Simpson G, Angus JA (1970) A rating scale for extra-pyramidal side-effects. Acta Psychiatr Scand 45 (Suppl. 212):11-19.
31. Stephens MDB (1992) The methodology of the collection of adverse event data in clinical trials. Detection of New Adverse Drug Reactions. MacMillan, New York 27, 37-70.
32. Webster DD (1968) Clinical analysis of the disability in Parkinson's disease. Mod Treat 5:257-282.
33. Wetzel H, Philipp M, Hillert A, Gattaz, WF, Sauer H, Adler G, et al., the Amisulpride Study Group (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. Psychopharmacology 137:223-232.